Mengwei Li

TL;DR: The lncRNA-TTN-AS1/miR133b/FSCN1 regulatory axis provides bona fide targets for anti-ESCC therapies and provides additional prognostic evidence for ESCC patients.

TL;DR: In this article , the authors summarized lifestyle changes and pharmacological medications that have been used as efficient intervention to improve insulin sensitivity and concluded that the systematic discussion of complex mechanism will help to identify potential new targets and treat the closely associated metabolic syndrome of IR.

TL;DR: The evidence and knowledge on the contribution of integrins to cancer biology are discussed and the clinical attempts targeting this family in anti-cancer therapy development are summarized.

TL;DR: The data indicate that FHBM can accurately control timing and dose of injected CAR-T cells, and sdCAR-T Cells exert significant antitumor activity while releasing lower levels of cytokines for the cognate tumor cells expressing both MSLN and integrin αvβ3.

TL;DR: Preclinical evidence is provided to support a novel strategy of ASOs targeting AC104041.1 in combination with salinomycin and may as a beneficial treatment approach for HNSCC.